Published in Blood Weekly, January 29th, 2009
"We are very pleased with the Advisory Committee's recommendation in support of the safety and efficacy of ATryn," said...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.